<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230829000933&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230829000933&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 29 Aug 2023 04:09:35 +0000</lastbuilddate>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>What Is a Normal Left Ventricular Ejection Fraction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639509</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161/CIRCULATIONAHA.123.065791</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639509</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Paul Heidenreich</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>What Is a Normal Left Ventricular Ejection Fraction?</dc:title>
<dc:identifier>pmid:37639509</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065791</dc:identifier>
</item>
<item>
<title>Response by Ostadal and Belohlavek to Letter Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):804. doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639508</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639508</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Petr Ostadal</dc:creator>
<dc:creator>Jan Belohlavek</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Ostadal and Belohlavek to Letter Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:37639508</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065358</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639507/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):798-799. doi: 10.1161/CIRCULATIONAHA.123.066278. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639507/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639507</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066278>10.1161/CIRCULATIONAHA.123.066278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639507</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:37639507</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066278</dc:identifier>
</item>
<item>
<title>Letter by Ferreira Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639506</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639506</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jorge Ferreira</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Ferreira Regarding Article, "Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:37639506</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063622</dc:identifier>
</item>
<item>
<title>Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 29;148(9):800-802. doi: 10.1161/CIRCULATIONAHA.123.066131. Epub 2023 Aug 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639505</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161/CIRCULATIONAHA.123.066131</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639505</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nisha Donthi</dc:creator>
<dc:creator>Catherine R Lucey</dc:creator>
<dc:creator>Michelle A Albert</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stages of Dismantling Structural Racism in Medicine: A Focus on Medical Training</dc:title>
<dc:identifier>pmid:37639505</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066131</dc:identifier>
</item>
<item>
<title>Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093/eurheartj/ehad595. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: There is little information on the incremental prognostic importance of frailty beyond conventional prognostic variables in heart failure (HF) populations from different country income levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 3429 adults with HF (age 61±14 years, 33% women) from 27 high-, middle- and low-income countries were prospectively studied. Baseline frailty was evaluated by the Fried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss and self-reported exhaustion. Mean left ventricular ejection fraction was 39±14% and 26% had New York Heart Association (NYHA) class III/IV symptoms. Participants were followed for a median (25th-75th percentile) 3.1 (2.0-4.3) years. Cox proportional hazards models for death and HF hospitalization adjusted for country income level; age; sex; education; HF etiology; left ventricular ejection fraction; diabetes; tobacco and alcohol use; NYHA functional class; HF medication use; blood pressure; hemoglobin, sodium and creatinine concentrations were performed. The incremental discriminatory value of frailty over and above the MAGGIC risk score was evaluated by the area under the receiver-operating characteristic curve.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, 18% of participants were robust, 61% pre-frail and 21% frail. During follow-up, 565 (16%) participants died and 471 (14%) were hospitalized for HF. Respective adjusted hazard ratios [HRs (95% CI)] for death among the prefrail and frail were 1.59 (1.12-2.26) and 2.92 (1.99-4.27). Respective adjusted HRs (95% CI) for HF hospitalization were 1.32 (0.93-1.87) and 1.97 (1.33-2.91). Findings were consistent among different country income levels and by most subgroups. Adding frailty to the MAGGIC risk score improved the discrimination of future death and HF hospitalization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639487</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639487</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Darryl P Leong</dc:creator>
<dc:creator>Philip Joseph</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Jean Rouleau</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Fernando Lanas</dc:creator>
<dc:creator>Sanjib K Sharma</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Bishav Mohan</dc:creator>
<dc:creator>Ahmet Celik</dc:creator>
<dc:creator>Jabir Abdullakutty</dc:creator>
<dc:creator>Okechukwu S Ogah</dc:creator>
<dc:creator>Lisa M Mielniczuk</dc:creator>
<dc:creator>Kumar Balasubramanian</dc:creator>
<dc:creator>Tara McCready</dc:creator>
<dc:creator>Alex Grinvalds</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>P Joseph</dc:creator>
<dc:creator>G-CHF Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</dc:title>
<dc:identifier>pmid:37639487</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad595</dc:identifier>
</item>
<item>
<title>Third generation PCSK9-Inhibitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad566. doi: 10.1093/eurheartj/ehad566. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639486</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ulrich Laufs</dc:creator>
<dc:creator>Matthias Blüher</dc:creator>
<dc:creator>Berend Isermann</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Third generation PCSK9-Inhibitors</dc:title>
<dc:identifier>pmid:37639486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad566</dc:identifier>
</item>
<item>
<title>Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093/eurheartj/ehad561. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterise the cardiac complications of EMD variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutively referred EMD variant-carriers were retrospectively recruited from 12 international cardiomyopathy units. MVA and ESHF incidence in male and female variant-carriers was determined. Male EMD variant-carriers with a cardiac phenotype at baseline (EMDCARDIAC) were compared to consecutively recruited male LMNA variant-carriers with a cardiac phenotype at baseline (LMNACARDIAC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Longitudinal follow-up data were available for 38 male and 21 female EMD variant-carriers (mean [SD] ages 33.4 [13.3] and 43.3 [16.8] years, respectively). Nine (23.6%) males developed MVA and five (13.2%) developed ESHF during a median [IQR] follow-up of 65.0 [24.3, 109.5] months. No female EMD variant-carrier had MVA or ESHF, but nine (42.8%) developed a cardiac phenotype at a median [IQR] age of 58.6 [53.2, 60.4] years. Incidence rates for MVA were similar for EMDCARDIAC and LMNACARDIAC (4.8 and 6.6 per 100 person-years, respectively; log-rank p = 0.49). Incidence rates for ESHF were 2.4 and 5.9 per 100 person-years for EMDCARDIAC and LMNACARDIAC, respectively (log-rank p = 0.09).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad561>10.1093/eurheartj/ehad561</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639473</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Douglas E Cannie</dc:creator>
<dc:creator>Petros Syrris</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Jean-François Pruny</dc:creator>
<dc:creator>Raffaello Ditaranto</dc:creator>
<dc:creator>Cristina Martinez-Veira</dc:creator>
<dc:creator>Jose M Larrañaga-Moreira</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Francisco José Bermúdez-Jiménez</dc:creator>
<dc:creator>Rabah Ben Yaou</dc:creator>
<dc:creator>France Leturq</dc:creator>
<dc:creator>Ainhoa Robles Mezcua</dc:creator>
<dc:creator>Chiara Marini-Bettolo</dc:creator>
<dc:creator>Eva Cabrera</dc:creator>
<dc:creator>Chloe Reuter</dc:creator>
<dc:creator>Javier Limeres Freire</dc:creator>
<dc:creator>José F Rodríguez-Palomares</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Juan Jiménez-Jáimez</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>José M García Pinilla</dc:creator>
<dc:creator>John Bourke</dc:creator>
<dc:creator>Konstantinos Savvatis</dc:creator>
<dc:creator>Karim Wahbi</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</dc:title>
<dc:identifier>pmid:37639473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad561</dc:identifier>
</item>
<item>
<title>Frailty: A new Vital Sign in Heart Failure Comes of age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093/eurheartj/ehad559. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639470</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad559>10.1093/eurheartj/ehad559</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639470</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Finlay A McAlister</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty: A new Vital Sign in Heart Failure Comes of age</dc:title>
<dc:identifier>pmid:37639470</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad559</dc:identifier>
</item>
<item>
<title>Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad596. doi: 10.1093/eurheartj/ehad596. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Lerodalcibep, a novel small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 ml SC dosing in Phase 2. In this global Phase 3 trial, the safety and efficacy of lerodalcibep was evaluated in heterozygous familial hypercholesterolaemia (HeFH) patients requiring additional LDL-C lowering.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were randomized 2:1 to monthly SC injections of either lerodalcibep 300 mg or placebo for 24 weeks. The primary efficacy endpoints were the percent change from baseline in LDL-C at Week 24 and the mean of Weeks 22 and 24.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 478 randomized subjects [mean age (range); 53 (18-80) years, 51.7% female, mean (SD) baseline LDL-C 3.88 (1.66) mmol/L] lerodalcibep reduced LDL-C, compared to placebo by an absolute amount of 2.08 (0.11) mmol/L [LS mean(SE); 95% CI -2.30 to -1.87] with a percentage difference of -58.61 (3.25)% at Week 24 and by 2.28 (0.10) mmol/L (95% CI -2.47 to -2.09) with a percentage difference of -65.0 (2.87)% at the mean of Weeks 22 and 24 (P &lt; 0.0001 for all). With lerodalcibep, 68% of subjects achieved both a reduction in LDL-C ≥ 50% and the recommended ESC LDL-C targets during the study. Except for mild injection site reactions, treatment-emergent adverse events were similar between lerodalcibep and placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639462</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad596>10.1093/eurheartj/ehad596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639462</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederick Raal</dc:creator>
<dc:creator>Nyda Fourie</dc:creator>
<dc:creator>Russell Scott</dc:creator>
<dc:creator>Dirk Blom</dc:creator>
<dc:creator>Matthys De Vries Basson</dc:creator>
<dc:creator>Meral Kayikcioglu</dc:creator>
<dc:creator>Kate Caldwell</dc:creator>
<dc:creator>David Kallend</dc:creator>
<dc:creator>Evan Stein</dc:creator>
<dc:creator>LIBerate-HeFH Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</dc:title>
<dc:identifier>pmid:37639462</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad596</dc:identifier>
</item>
<item>
<title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3357. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639276</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3357>10.1001/jamacardio.2023.3357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639276</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37639276</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3357</dc:identifier>
</item>
<item>
<title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3045. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639265</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3045>10.1001/jamacardio.2023.3045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639265</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China</dc:title>
<dc:identifier>pmid:37639265</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3045</dc:identifier>
</item>
<item>
<title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P &lt; .001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m2; 95% CI, -41.6 to -20.1 g/m2). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05174416.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639259</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3030>10.1001/jamacardio.2023.3030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639259</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhuang Tian</dc:creator>
<dc:creator>Liwen Li</dc:creator>
<dc:creator>Xiaoyan Li</dc:creator>
<dc:creator>Jian'an Wang</dc:creator>
<dc:creator>Qing Zhang</dc:creator>
<dc:creator>Zhanquan Li</dc:creator>
<dc:creator>Daoquan Peng</dc:creator>
<dc:creator>Ping Yang</dc:creator>
<dc:creator>Wei Ma</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Wei Jin</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:creator>Jing Sun</dc:creator>
<dc:creator>Yiqun Fu</dc:creator>
<dc:creator>Cheng Lyu</dc:creator>
<dc:creator>Shuyang Zhang</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37639259</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3030</dc:identifier>
</item>
<item>
<title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 28. doi: 10.1001/jamacardio.2023.3342. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, -34.0 mm Hg; 95% CI, -43.5 to -24.5 mm Hg and -33.2 mm Hg; 95% CI, -41.9 to -24.5 mm Hg) and Valsalva (mean difference, -45.6 mm Hg; 95% CI, -56.5 to -34.6 mm Hg and -54.6 mm Hg; 95% CI, -66.0 to -43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04349072.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639243</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3342>10.1001/jamacardio.2023.3342</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639243</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Jeffrey B Geske</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Mark Sherrid</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>David Fermin</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Nicholas G Smedira</dc:creator>
<dc:creator>Hartzell Schaff</dc:creator>
<dc:creator>Ellen McErlean</dc:creator>
<dc:creator>Christina Sewell</dc:creator>
<dc:creator>Lana Mudarris</dc:creator>
<dc:creator>Zhiqun Gong</dc:creator>
<dc:creator>Kathy Lampl</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37639243</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3342</dc:identifier>
</item>
<item>
<title>Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093/eurheartj/ehad592. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders. HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset AF compared to sinus rhythm (SR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adults with new-onset AF (n = 1,747) or SR (n = 29,623) and no structural heart disease were identified. Propensity-score matching was performed (1:3 ratio) between AF and SR based on age, sex, body mass index, and comorbidities. Severe DD (SDD) was defined by ≥3/4 abnormal parameters (medial e', medial E/e', tricuspid regurgitation velocity, left atrial volume index) and ≥moderate (MDD) by ≥2/4. Annualised changes in DD indices were determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: New-onset AF was independently associated with SDD (8% vs 3%) and ≥MDD (25% vs 16%). 62% of patients with AF had high-risk H2FPEF scores and 5% had clinically-recognised HFpEF. Over a median follow-up of 3.2 (interquartile range 1.6-5.8) years, DD progressed 2-4-fold more rapidly in those with new-onset AF (p &lt; 0.001 for all). Risk for incident DD was increased i new-onset AF [hazard ratio (95% confidence interval) 2.69 (2.19-3.32) for SDD and 1.73 (1.49-2.02) for ≥MDD].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with new-onset AF display high-risk features for HFpEF at diagnosis, emphasizing the importance of evaluating for HFpEF among symptomatic patients with AF. Patients with new-onset AF have accelerated progression in DD over time, which may identify patients with preclinical HFpEF, where preventive therapies may be tested.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37639219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37639219</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad592>10.1093/eurheartj/ehad592</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37639219</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Christopher G Scott</dc:creator>
<dc:creator>Austin M Kennedy</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Grace Lin</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications</dc:title>
<dc:identifier>pmid:37639219</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad592</dc:identifier>
</item>
<item>
<title>Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad569. doi: 10.1093/eurheartj/ehad569. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638993</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad569>10.1093/eurheartj/ehad569</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638993</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ratika Parkash</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive</dc:title>
<dc:identifier>pmid:37638993</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad569</dc:identifier>
</item>
<item>
<title>Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad564. doi: 10.1093/eurheartj/ehad564. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: High percentages of atrial pacing have been associated with an increased risk of atrial fibrillation. This study aimed at evaluating whether atrial pacing minimization in patients with sinus node dysfunction reduces the incidence of atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a nationwide, randomized controlled trial, 540 patients with sinus node dysfunction and an indication for first pacemaker implantation were assigned to pacing programmed to a base rate of 60 bpm and rate-adaptive pacing (DDDR-60) or pacing programmed to a base rate of 40 bpm without rate-adaptive pacing (DDD-40). Patients were followed on remote monitoring for 2 years. The primary endpoint was time to first episode of atrial fibrillation longer than 6 min. Secondary endpoints included longer episodes of atrial fibrillation, and the safety endpoint comprised a composite of syncope or presyncope.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median percentage of atrial pacing was 1% in patients assigned to DDD-40 and 49% in patients assigned to DDDR-60. The primary endpoint occurred in 124 patients (46%) in each treatment group (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.76-1.25, P=0.83). There were no between-group differences in atrial fibrillation exceeding 6- or 24 hours, persistent atrial fibrillation, or cardioversions for atrial fibrillation. The incidence of syncope or presyncope was higher in patients assigned to DDD-40 (HR 1.71 95% CI 1.13-2.59, P=0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Atrial pacing minimization in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation. Programming a base rate of 40 bpm without rate-adaptive pacing is associated with an increased risk of syncope or presyncope.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638973</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad564>10.1093/eurheartj/ehad564</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638973</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mads Brix Kronborg</dc:creator>
<dc:creator>Maria Hee Jung Park Frausing</dc:creator>
<dc:creator>Jerzy Malczynski</dc:creator>
<dc:creator>Sam Riahi</dc:creator>
<dc:creator>Jens Haarbo</dc:creator>
<dc:creator>Katja Fiedler Holm</dc:creator>
<dc:creator>Charlotte Ellen Larroudé</dc:creator>
<dc:creator>Andi Eie Albertsen</dc:creator>
<dc:creator>Lene Svendstrup</dc:creator>
<dc:creator>Ulrik Hintze</dc:creator>
<dc:creator>Ole Dyg Pedersen</dc:creator>
<dc:creator>Ulla Davidsen</dc:creator>
<dc:creator>Thomas Fischer</dc:creator>
<dc:creator>Jens Brock Johansen</dc:creator>
<dc:creator>Jens Kristensen</dc:creator>
<dc:creator>Christian Gerdes</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>DANPACE II Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial</dc:title>
<dc:identifier>pmid:37638973</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad564</dc:identifier>
</item>
<item>
<title>Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 28. doi: 10.1161/CIRCULATIONAHA.123.066360. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. <b>Methods:</b> In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with isolated distal DVT, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary endpoint was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary endpoint was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary endpoint. <b>Results:</b> From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of DVT at baseline. The primary endpoint of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03 to 0.44). The major secondary endpoint of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75 to 2.41). The prespecified subgroups did not affect the estimates on the primary endpoint. <b>Conclusions:</b> In cancer patients with isolated distal DVT, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638968</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066360>10.1161/CIRCULATIONAHA.123.066360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638968</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Yugo Yamashita</dc:creator>
<dc:creator>Takeshi Morimoto</dc:creator>
<dc:creator>Nao Muraoka</dc:creator>
<dc:creator>Takuya Oyakawa</dc:creator>
<dc:creator>Michihisa Umetsu</dc:creator>
<dc:creator>Daijirou Akamatsu</dc:creator>
<dc:creator>Yuji Nishimoto</dc:creator>
<dc:creator>Yukihito Sato</dc:creator>
<dc:creator>Takuma Takada</dc:creator>
<dc:creator>Kentaro Jujo</dc:creator>
<dc:creator>Yuichiro Minami</dc:creator>
<dc:creator>Yoshito Ogihara</dc:creator>
<dc:creator>Kaoru Dohi</dc:creator>
<dc:creator>Masashi Fujita</dc:creator>
<dc:creator>Tatsuya Nishikawa</dc:creator>
<dc:creator>Nobutaka Ikeda</dc:creator>
<dc:creator>Go Hashimoto</dc:creator>
<dc:creator>Kazunori Otsui</dc:creator>
<dc:creator>Kenta Mori</dc:creator>
<dc:creator>Daisuke Sueta</dc:creator>
<dc:creator>Yukari Tsubata</dc:creator>
<dc:creator>Masaaki Shoji</dc:creator>
<dc:creator>Ayumi Shikama</dc:creator>
<dc:creator>Yutaka Hosoi</dc:creator>
<dc:creator>Yasuhiro Tanabe</dc:creator>
<dc:creator>Ryuki Chatani</dc:creator>
<dc:creator>Kengo Tsukahara</dc:creator>
<dc:creator>Naohiko Nakanishi</dc:creator>
<dc:creator>Kitae Kim</dc:creator>
<dc:creator>Satoshi Ikeda</dc:creator>
<dc:creator>Makoto Mo</dc:creator>
<dc:creator>Yusuke Yoshikawa</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>ONCO DVT Study Investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37638968</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066360</dc:identifier>
</item>
<item>
<title>Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad567. doi: 10.1093/eurheartj/ehad567. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The European Union Medical Device Regulation 2017/745 challenges key stakeholders to follow transparent and rigorous approaches to the clinical evaluation of medical devices. The purpose of this study is a systematic evaluation of published clinical evidence underlying selected high-risk cardiovascular medical devices before and after market access in the European Union (CE marking) between 2000 and 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Prespecified strategies were applied to identify published studies of prospective design evaluating 71 high-risk cardiovascular devices in 7 different classes (bioresorbable coronary scaffolds, left atrial appendage occlusion devices, transcatheter aortic valve implantation systems, transcatheter mitral valve repair/replacement systems, surgical aortic and mitral heart valves, leadless pacemakers, subcutaneous implantable cardioverter-defibrillator). The search time-span covered 20 years (2000-2021). Details of study design, patient population, intervention(s) and primary outcome(s) were summarized, and assessed with respect to timing of the corresponding CE-mark approval.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At least one prospective clinical trial was identified for 70% (50/71) of the prespecifed devices. Overall, 473 reports of 308 prospectively designed studies (enrolling 97,886 individuals) were deemed eligible, including 81% (251/308) prospective non-randomized clinical trials (66,186 individuals) and 19% (57/308) randomized clinical trials (31,700 individuals). Preregistration of the study protocol was available in 49% (150/308) studies, and 16% (48/308) had a peer-reviewed publicly available protocol. Device-related adverse events were evaluated in 82% (253/308) of studies. An outcome adjudication process was reported in 39% (120/308) of the studies. Sample size was larger for randomized in comparison to non-randomized trials (median of 304 versus 100 individuals, p&lt;0.001). No randomized clinical trial published before CE-mark approval for any of the devices was identified. Non-randomized clinical trials were predominantly published after the corresponding CE-mark approval of the device under evaluation (89%, 224/251). Sample sizes were smaller for studies published before (median of 34 individuals) than after (median of 135 individuals) CE-mark approval (p&lt;0.001). Clinical trials with larger sample sizes (>;50 individuals) and those with longer recruitment periods were more likely to be published after CE-mark approval, and were more frequent during the period 2016-2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The quantity and quality of publicly available data from prospective clinical investigations across selected categories of cardiovascular devices, before and after CE approval during the period 2000-2021, was deemed insufficient. The majority of studies were non-randomized, with increased risk of bias, and performed in small populations without provision of power calculations, and none of the reviewed devices had randomized trial results published prior to CE mark certification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638967</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad567>10.1093/eurheartj/ehad567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638967</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>George Cm Siontis</dc:creator>
<dc:creator>Bernadette Coles</dc:creator>
<dc:creator>Jonas D Häner</dc:creator>
<dc:creator>Laurna McGovern</dc:creator>
<dc:creator>Joanna Bartkowiak</dc:creator>
<dc:creator>J J Coughlan</dc:creator>
<dc:creator>Alessandro Spirito</dc:creator>
<dc:creator>Roberto Galea</dc:creator>
<dc:creator>Andreas Haeberlin</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Daijiro Tomii</dc:creator>
<dc:creator>Tom Melvin</dc:creator>
<dc:creator>André Frenk</dc:creator>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>CORE-MD investigators</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium</dc:title>
<dc:identifier>pmid:37638967</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad567</dc:identifier>
</item>
<item>
<title>Type A aortic dissection: optimal annual case volume for surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad551. doi: 10.1093/eurheartj/ehad551. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The current study proposes a novel volume-outcome (V-O) meta-analytical approach to determine the optimal annual hospital case volume threshold for cardiovascular interventions in need of centralization. This novel method is applied to surgery for acute type A aortic dissection (ATAAD) as an illustrative example.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A systematic search was applied to three electronic databases (January 1st 2012 - March 29th 2023). The primary outcome was early mortality in relation to annual hospital case volume. Data were presented by volume quartiles (Qs). Restricted cubic splines were used to demonstrate the V-O relation, and the elbow method was applied to determine the optimal case volume. For clinical interpretation, numbers needed to treat (NNT) were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 140 studies were included, comprising 38276 patients. A significant non-linear V-O effect was observed (p&lt;0.001), with a significant between-quartile difference for early mortality (10.3% [Q4] vs. 16.2% [Q1], p&lt;0.001). The optimal annual case volume was determined at 38 cases/year (95% CI 37-40 cases/year, NNT to save a life in a centre with the optimal volume vs. 10 cases/year = 21). More pronounced between-quartile survival differences were observed for long-term survival (10-year survival [Q4] 69% vs. [Q1] 51%, p&lt;0.001, adjusted HR 0.83, 95% CI 0.75-0.91 per quartile, NNT to save a life in a high-volume [Q4] vs. low-volume centre [Q1) = 6).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using this novel approach, the optimal hospital case volume threshold was statistically determined. Centralization of ATAAD care to high-volume centres may lead to improved outcomes. This method can be applied to various other cardiovascular procedures requiring centralization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638786</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad551>10.1093/eurheartj/ehad551</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638786</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael J Kawczynski</dc:creator>
<dc:creator>Sander M J van Kuijk</dc:creator>
<dc:creator>Jules R Olsthoorn</dc:creator>
<dc:creator>Jos G Maessen</dc:creator>
<dc:creator>Suzanne Kats</dc:creator>
<dc:creator>Elham Bidar</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Type A aortic dissection: optimal annual case volume for surgery</dc:title>
<dc:identifier>pmid:37638786</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad551</dc:identifier>
</item>
<item>
<title>Acute type A aortic dissection: stay and play or load and run?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230829000933&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 28:ehad517. doi: 10.1093/eurheartj/ehad517. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37638778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230829000933&v=2.17.9.post6+86293ac">37638778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad517>10.1093/eurheartj/ehad517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37638778</guid>
<pubDate>Mon, 28 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Tim Berger</dc:creator>
<dc:creator>Maximilian Kreibich</dc:creator>
<dc:creator>Martin Czerny</dc:creator>
<dc:date>2023-08-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute type A aortic dissection: stay and play or load and run?</dc:title>
<dc:identifier>pmid:37638778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad517</dc:identifier>
</item>





























</channel>
</rss>